US SEC Filing Intelligence

DHS Homeland Security Contracts — May 02, 2026

A single DHS contract totaling $9,401,259 in obligations was analyzed, representing 100% civilian activity with zero defense-related components. The U.S. Coast Guard awarded Lockheed Martin Corporation a sole-source, cost-plus-fixed-fee contract for C4ISR integration and test laboratory services, spanning May 2022 to May 2027 in Moorestown, NJ. This neutral signal (strength 3/10, materiality 2/10) adds modestly to Lockheed Martin's federal IT services portfolio (NAICS 541513, PSC DC01), with estimated annual revenue of ~$1.88M. The highest-conviction signal is low materiality relative to Lockheed's scale, providing minimal sector impact. A key risk/watch item is zero funds outlayed to date despite $9.4M obligated, alongside $1.15M in unexercised options.

HHS & Healthcare Contracts Intelligence — May 02, 2026

The analyzed contracts total $269,952,453 in obligations, representing a 100% civilian split with zero defense-related awards, dominated by HHS's Office of Assistant Secretary for Preparedness and Response (ASPR) via BARDA Ventures. GLOBAL HEALTH INVESTMENT CORPORATION, a New York-based nonprofit, secured this $269,952,453 firm fixed price Definitive Contract on 2021-05-25 for health R&D (NAICS 541715, PSC AN41), with $241,937,500 (90%) already outlayed over the initial performance period from 2021-06-01 to 2031-06-01. The highest-conviction signal is neutral (4/10 strength), highlighting sustained federal funding for long-term health preparedness R&D but limited direct appeal for equity portfolios due to the recipient's nonprofit status. A key risk is high contract pricing risk under the firm fixed price structure within the BARDA Ventures Other Transaction Agreement. Watch outlay progress on the remaining ~$28 million obligation toward the 2031 current end date or potential extension to 2041.

New Federal Contractors — May 02, 2026

This digest synthesizes $1,718,415,049 in total obligations across 5 new civilian federal contracts (0/5 defense-related) awarded primarily to DOE, USDA, HHS, GSA, and DHS, highlighting civilian agency commitments to nuclear materials production, IT software/support, health R&D, financial services, and C4ISR lab services. Dominant sector themes include strategic nuclear capacity buildup via DOE's $900M award to ORANO FEDERAL SERVICES LLC and sustained IT investments like USDA's $294.6M Salesforce deal with CARAHSOFT TECHNOLOGY CORP. The highest-conviction bullish signal is CARAHSOFT TECHNOLOGY CORP's fully obligated and outlayed $294.6M USDA contract (strength 8/10), signaling reliable revenue through 2025. Balanced by neutral signals for nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS) and modest LOCKHEED MARTIN ($9.4M DHS). Key risk: High pricing risk on firm-fixed-price structures across top awards (ORANO, CARAHSOFT, GLOBAL HEALTH), with watch on initial outlays post-May 2026 starts.

Significant Contract Modifications ($10M+) — May 02, 2026

This digest covers five significant civilian contract modifications totaling $1,718,415,049 in obligations, with 0/5 defense-related awards across DOE, USDA, HHS, GSA, and DHS. Dominant themes include strategic nuclear materials production (DOE/ORANO $900M) and IT/software services (USDA/Carahsoft $295M), underscoring civilian agency commitments to energy security and enterprise tech upgrades. Highest-conviction bullish signal is Carahsoft Technology Corp's fully obligated and outlayed $294.6M USDA Salesforce contract (strength 8/10), signaling reliable revenue through 2025. Key risk is high pricing risk on firm-fixed-price structures across top awards (ORANO, Carahsoft, GLOBAL HEALTH), with watch on initial outlays for ORANO's LEU production post-May 2026 start.

Contract Deobligations Alert — May 02, 2026

This Contract Deobligations Alert synthesizes $1,718,415,049 in total obligations across 5 civilian contracts (0 defense-related) awarded by DOE, USDA, HHS, GSA, and DHS, highlighting sustained federal commitments in nuclear materials, IT software, health R&D, financial services, and C4ISR support. Dominant themes include DOE's $900M push for domestic LEU production via ORANO FEDERAL SERVICES LLC and USDA's $294.6M Salesforce investment with CARAHSOFT TECHNOLOGY CORP, both full and open competition firm-fixed price awards. Highest-conviction signal is bullish for CARAHSOFT (strength 8/10, materiality 9/10) given full obligation and outlays on a 5-year USDA IT contract. Balanced by neutral signals for nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS R&D) and small Lockheed Martin ($9.4M DHS) addition. Key risk: High pricing risk on firm-fixed structures across top contracts, with watch on initial outlays for ORANO post-May 2026 start.

Contract Option Exercises — May 02, 2026

This digest covers five civilian agency contract option exercises totaling $1,718,415,049 in obligations, with zero defense-related awards, highlighting sustained federal investment in nuclear materials, IT software, health R&D, financial services, and DHS IT support. Dominant themes include DOE's $900M commitment to domestic low-enriched uranium production via ORANO FEDERAL SERVICES LLC and USDA's fully outlayed $295M Salesforce deployment with CARAHSOFT TECHNOLOGY CORP, representing the highest-conviction bullish signals at 8/10 strength. BANK OF NEW YORK MELLON's $244M GSA financial services contract adds steady revenue visibility with $189M already outlayed. Neutral signals from GLOBAL HEALTH INVESTMENT CORPORATION's $270M HHS health R&D and Lockheed Martin's modest $9M DHS C4ISR lab services temper overall momentum. Key risk is high pricing risk across firm-fixed-price structures, with watch on initial outlays for ORANO post-May 2026 start and performance milestones to 2033.

Federal IT & Cybersecurity Contracts — May 02, 2026

The single contract analyzed totals $294,589,912 in obligations, entirely civilian with zero defense exposure, centered on Department of Agriculture's enterprise-wide Salesforce software and support services via Carahsoft Technology Corp. This firm fixed-price delivery order, fully obligated and outlayed under full and open competition, provides a bullish signal for Carahsoft with high materiality (9/10) and strength (8/10), representing an estimated $58.9M in annual revenue through its 5-year performance period ending June 19, 2025. The dominant theme is USDA Office of the Chief Financial Officer's sustained IT modernization investment in NAICS 541519 and PSC 7030 categories. Highest-conviction signal is revenue visibility for Carahsoft in civilian federal IT reselling. Key watch item is the contract's performance end date of 2025-06-19 for potential follow-on opportunities amid high pricing execution risk.

All HHS Contracts — May 02, 2026

HHS awarded GLOBAL HEALTH INVESTMENT CORPORATION, a New York nonprofit, a single $269,952,453 firm fixed price contract under BARDA Ventures OTA for health R&D services (PSC AN41, NAICS 541715), representing a 0/1 defense/civilian split with full civilian focus via HHS/ASPR. With $241,937,500 (90%) already outlayed since the 2021-05-25 award, this underscores a dominant theme of long-term health preparedness R&D commitment through 2031-06-01 (potential 2041-06-01). The highest-conviction neutral signal (4/10 strength, 6/10 materiality) highlights sustained federal funding stability absent equity appeal. Key risk: high pricing risk under firm fixed price structure. Watch outlay progress on the remaining ~$28M obligation.

All DOE Contracts — May 02, 2026

The DOE awarded a single $900,000,000 firm fixed price delivery order to ORANO FEDERAL SERVICES LLC for establishing domestic low-enriched uranium (LEU) production capacity, representing full civilian exposure with zero defense-related contracts. This contract, managed by the DOE Idaho Operations Office under full and open competition, signals strong commitment to strategic nuclear materials over a 7-year period from May 1, 2026, to April 30, 2033. The highest-conviction bullish signal is ORANO FEDERAL SERVICES LLC's $900M obligation, estimating ~$128.6M annual revenue and bolstering the nuclear sector amid DOE priorities. Key risk includes high pricing risk due to firm fixed price structure, with investors watching initial outlays post-May 1, 2026, and LEU capacity milestones.

Mega Contracts Monitor ($100M+) — May 02, 2026

Four civilian mega contracts totaling $1,709,013,790 in obligations highlight sustained federal commitments across DOE, USDA, HHS, and GSA, with zero defense-related awards. The dominant theme is strategic civilian investments, led by DOE's highest-materiality $900M award to ORANO FEDERAL SERVICES LLC for low-enriched uranium production. Highest-conviction bullish signal is CARAHSOFT TECHNOLOGY CORP's fully obligated and outlayed $294.6M USDA Salesforce contract (strength 8/10). Neutral signal from GLOBAL HEALTH INVESTMENT CORPORATION's $270M HHS health R&D award to a nonprofit limits direct equity upside. Key risk is high pricing risk on all firm-fixed-price structures; watch ORANO's initial outlays and LEU capacity milestones post-2026-05-01.

4 total filings

High-Value Federal Grants ($5M+) — May 02, 2026

This digest covers five high-value civilian federal grants totaling $1,718,415,049 in obligations from May 02, 2026 (0 defense-related), highlighting sustained civilian agency investments in nuclear materials, IT software, health R&D, financial services, and data center support. Dominant themes include DOE's massive commitment to domestic LEU production via ORANO FEDERAL SERVICES LLC ($900M, highest materiality) and USDA's fully executed Salesforce deal with CARAHSOFT TECHNOLOGY CORP ($294.6M). Highest-conviction bullish signal is ORANO's 7-year firm fixed-price delivery order, signaling strategic nuclear sector growth amid energy security priorities. Balanced by neutral signals from nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS R&D) and modest Lockheed Martin DHS award ($9.4M). Key risk: High pricing risk on firm fixed-price structures across top awards, with watch on initial outlays for ORANO post-May 2026 start.

DOE Energy Grants — May 02, 2026

The Department of Energy awarded a single $900,000,000 firm fixed price delivery order to ORANO FEDERAL SERVICES LLC for establishing domestic low-enriched uranium (LEU) production capacity, marking a full civilian allocation with 0/1 defense-related contracts. This DOE Idaho Operations Office contract, spanning May 1, 2026, to April 30, 2033, signals strong commitment to strategic nuclear materials under NAICS 325180 and PSC 6850 via full and open competition. The highest-conviction bullish signal is the 7-year $900M obligation, estimating $128.6M annual revenue for ORANO FEDERAL SERVICES LLC despite no outlays to date. A key risk is high contract pricing risk given the firm fixed price structure and capacity ramp-up uncertainties. Investors should monitor initial outlays post-May 1, 2026, as a near-term validation trigger.

General Federal Contracts — May 02, 2026

These five civilian federal contracts total $1,718,415,049 in obligations with 0/5 defense-related, spanning DOE nuclear materials, USDA IT software, HHS health R&D, GSA financial services, and DHS Coast Guard IT support. Dominant themes include strategic low-enriched uranium production via DOE's $900M award to ORANO FEDERAL SERVICES LLC and enterprise Salesforce support via USDA's $294.6M award to CARAHSOFT TECHNOLOGY CORP, signaling civilian agency commitments to critical infrastructure and IT modernization. Highest-conviction signal is bullish for CARAHSOFT TECHNOLOGY CORP (strength 8/10) due to full obligation and outlays on its 5-year USDA contract. ORANO FEDERAL SERVICES LLC's $900M DOE award offers the largest materiality (9/10) for long-term nuclear capacity. Key risk is high pricing risk on firm fixed price structures across ORANO, CARAHSOFT, GLOBAL HEALTH INVESTMENT CORPORATION, and BANK OF NEW YORK MELLON contracts, with watch on initial outlays for ORANO post-May 1, 2026.

Biotech Small-Cap Approvals — May 01, 2026

The period captured 1 FDA approval in the biotech small-cap stream: 0 NMEs, 0 biosimilars (classified as 1 other/fallback), 0 label expansions. Micro Labs' ticagrelor approval (2026-04-27) delivers a single neutral signal (strength 5/10, materiality 5/10), representing fallback biosimilar entry with all commercial metrics NOT_DISCLOSED, including peak sales, exclusivity, pricing power, and market position. No dominant therapeutic area theme emerges from this lone approval. Highest-conviction signal is ticagrelor by Micro Labs, implying modest, neutral commercial access for the entrant alongside potential erosion risk for the originator. Key risk/watch item: lack of disclosed commercial data obscures launch potential and competitive dynamics for Micro Labs and ticagrelor originator.

Big Pharma Approvals — May 01, 2026

FDA approvals from May 01, 2026 to May 01, 2026 in the Big Pharma stream totaled 1: 0 NME(s), 0 Biosimilar(s), 0 Label Expansion(s), 1 Other. AstraZeneca AB's BUDESONIDE (BREZTRI AEROSPHERE) label expansion approval delivers the period's highest-conviction bullish signal (strength 5/10, materiality 5/10), potentially strengthening its market position in an undisclosed therapeutic area despite all commercial metrics (peak sales, exclusivity, pricing) remaining NOT_DISCLOSED. No dominant therapeutic area theme is evident from this solitary approval. Balanced upside exists via expanded labeling, but risks include lack of disclosed near-term catalysts (N/A) and opaque market positioning. Key risk/watch item: monitor post-approval uptake and any emerging competitive dynamics for BREZTRI AEROSPHERE.

Orphan Drug Approvals — May 01, 2026

In the May 01, 2026 period, the FDA approved 1 orphan drug (0 NME, 0 biosimilar, 0 label expansion, 1 other), marking a bullish signal in the orphan space. Daiichi Sankyo's FAM-TRASTUZUMAB DERUXTECAN-NXKI (ENHERTU) label expansion represents the highest-conviction event, signaling potential upside in orphan indications with a strength of 5/10 and materiality of 5/10. No dominant therapeutic area theme emerges from this single approval. Key commercial details including peak sales, exclusivity, pricing power, and market position remain NOT_DISCLOSED, tempering near-term visibility. Investors should watch for post-approval uptake and any confirmatory data requirements inherent in orphan expansions.

New Drug Approvals (Original) — May 01, 2026

FDA approvals from May 01, 2026 to May 01, 2026 totaled 1, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other. Micro Labs secured FDA approval for TICAGRELOR, a fallback approval categorized as neutral (strength 5/10, materiality 5/10) with no disclosed peak sales, exclusivity, pricing, or market position data. No dominant therapeutic area theme emerged from this single approval. The highest-conviction signal is Micro Labs' TICAGRELOR approval, offering neutral commercial implications as a market entrant with limited near-term catalysts. Key risk/watch item: competitive pressure on AstraZeneca's originator TICAGRELOR (Brilinta) from this new entrant, potentially leading to revenue erosion.